Jump to navigation Jump to search
Clinical data
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass413.55 g/mol
563.64 g/mol (tartrate)
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Lasofoxifene


Most recent articles on Lasofoxifene

Most cited articles on Lasofoxifene

Review articles on Lasofoxifene

Articles on Lasofoxifene in N Eng J Med, Lancet, BMJ


Powerpoint slides on Lasofoxifene

Images of Lasofoxifene

Photos of Lasofoxifene

Podcasts & MP3s on Lasofoxifene

Videos on Lasofoxifene

Evidence Based Medicine

Cochrane Collaboration on Lasofoxifene

Bandolier on Lasofoxifene

TRIP on Lasofoxifene

Clinical Trials

Ongoing Trials on Lasofoxifene at Clinical

Trial results on Lasofoxifene

Clinical Trials on Lasofoxifene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lasofoxifene

NICE Guidance on Lasofoxifene


FDA on Lasofoxifene

CDC on Lasofoxifene


Books on Lasofoxifene


Lasofoxifene in the news

Be alerted to news on Lasofoxifene

News trends on Lasofoxifene


Blogs on Lasofoxifene


Definitions of Lasofoxifene

Patient Resources / Community

Patient resources on Lasofoxifene

Discussion groups on Lasofoxifene

Patient Handouts on Lasofoxifene

Directions to Hospitals Treating Lasofoxifene

Risk calculators and risk factors for Lasofoxifene

Healthcare Provider Resources

Symptoms of Lasofoxifene

Causes & Risk Factors for Lasofoxifene

Diagnostic studies for Lasofoxifene

Treatment of Lasofoxifene

Continuing Medical Education (CME)

CME Programs on Lasofoxifene


Lasofoxifene en Espanol

Lasofoxifene en Francais


Lasofoxifene in the Marketplace

Patents on Lasofoxifene

Experimental / Informatics

List of terms related to Lasofoxifene

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Lasofoxifene (INN) (proposed tradename Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy,[1] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published online November 4 in The Journal of the National Cancer Institute.

In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.

On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn. Lasofoxifene was approved in the EU under the brand name Fablyn by the EMEA in March 2009.[2]

Lasofoxifene is a desmethyl dihydro analog of nafoxidine.[3]


In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.[4][5]


  1. Gennari L, Merlotti D, Martini G, Nuti R (2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opin Investig Drugs. 15 (9): 1091&ndash, 103. doi:10.1517/13543784.15.9.1091. PMID 16916275.
  2. Fablyn - lasofoxifene
  3. Lednicer D, Emmert DE, Lyster SC, Duncan GW (September 1969). "Mammalian antifertility agents. VI. A novel sequence for the preparation of 1,2-disubstituted 3,4-dihydronaphthalenes". J. Med. Chem. 12 (5): 881–5. doi:10.1021/jm00305a038. PMID 5812203.
  4. Gennari L, Merlotti D, Nuti R (2010). "Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene". Clin Interv Aging. 5: 19–29. doi:10.2147/cia.s6083. PMC 2817938. PMID 20169039.
  5. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles R, Zanchetta J, Kendler D, Neven P, Eastell R, the PEARL Study Investigators (2010). "Lasofoxifene in Postmenopausal Women with Osteoporosis". N Engl J Med. 362 (8): 686–696. doi:10.1056/NEJMoa0808692. PMID 20181970.

External links